#VisualAbstract: Risankizumab was Non-Inferior to Ustekinumab for the Clinical Remission of Moderate-to-Severe Crohn’s Disease
Click here to read this study in the NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: inflammatory bowel disease (IBD)
Disease activity may be associated with sleep quality in pediatric patients with inflammatory bowel disease
1. In this retrospective study, it was found that inflammatory bowel disease (IBD) activity was associated with poorer sleep scores ...
Wellness Check: Sleep
Digital cognitive behavioral therapy improves insomnia symptoms in stroke survivors 1. In this randomized controlled trial, patients who received digital ...
Etrasimod improves clinical remission rates in patients with moderate-severe ulcerative colitis
1. In both ELEVATE UC 12 and ELEVATE UC 52, significantly greater patients in the etrasimod group achieved clinical remission ...
Antidepressants may improve symptoms in patients with inflammatory bowel disease
1. In this systematic review and meta-analysis, patients with inflammatory bowel disease (IBD) who took antidepressants had lower anxiety, depression, ...
Wellness Check: Mental Health
Childhood maltreatment may cause mental health problems 1. In this systematic review and meta-analysis of quasi-experimental studies, there was a ...
Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases
1. An increased incidence of new cardiovascular disease was seen in individuals with autoimmune disease compared to those without. 2. ...
Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease
1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab. 2. Patient-reported outcomes of stool frequency and abdominal ...
Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease
1. Compared to a placebo (withdrawal) group, patients maintained on subcutaneous risankizumab had greater rates of clinical remission. 2. Adverse ...
Risankizumab induction therapy is effective for moderate-to-severe Crohn’s disease
1. The risankizumab group showed greater clinical remission and endoscopic response rates compared to placebo across the ADVANCE and MOTIVATE ...